Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Reportedly, sarcopenia is associated with prognosis in advanced colorectal cancer (CRC) patients and can lead to reduced efficacy of targeted therapy. However, studies on the relationship between sarcopenia and the prognosis (or efficacy) of advanced CRC patients receiving fruquintinib targeted therapy remains scarce. Therefore, we conducted a comprehensive assessment of the relationship between nutritional status, inflammation, immune function, and cancer-related sarcopenia. We also investigated whether sarcopenia affects the therapeutic efficacy of fruquintinib targeted therapy.
Patients And Methods: In this retrospective study, sarcopenia and several markers of nutritional status and immune function were assessed in advanced CRC patients with fruquintinib therapy at the hospital. We used drug target mendelian randomization (MR) analysis to investigate the impact of fruquintinib on sarcopenia.
Results: Advanced CRC patients with sarcopenia had a poorer prognosis compared to those without sarcopenia. Furthermore, sarcopenia showed a strong correlation with various markers of nutritional status, immune function indicators, inflammation markers, quality of life scores, and the prognostic nutrition index. MR studies suggest that the spleen tyrosine kinase (SYK) gene is a key factor in the occurrence of sarcopenia associated with the use of fruquintinib.
Conclusion: Sarcopenia could be a prognostic factor in patients with advanced CRC receiving fruquintinib targeted therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12307208 | PMC |
| http://dx.doi.org/10.3389/fimmu.2025.1582308 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical evaluation of folate receptor-alpha chimeric antigen receptor T cells (FOLR1-CART) exhibit highly efficient anti-tumor activity against osteosarcoma.
Cancer Res Commun
September 2025
Fred Hutchinson Cancer Center, Seattle, WA, United States.
Metastatic and relapsed osteosarcoma (OS) remains difficult to treat despite advanced surgical techniques, intensified chemotherapy, and targeted therapies. Adoptive immunotherapies such as chimeric antigen receptor (CAR) T cells, are in their nascent stage, but remain a viable therapeutic strategy for patients with aggressive solid tumors such as OS. Folate receptor- (FOLR1) has been functionally implicated in OS pathophysiology, providing rationale as a potential therapeutic target.
View Article and Find Full Text PDFThe effectiveness of three months EGFR-CTH therapy in palliative colorectal cancer.
Rep Pract Oncol Radiother
August 2025
Cardiac Surgery and Transplantology Department, Poznan University of Medical Sciences, Poznan, Poland.
Background: The rising burden of colorectal cancer with a high prevalence of advanced stages of new-onset is reported worldwide. While applied, chemotherapy can extend patients' survival, and proper tailoring is paramount. Based on computed tomography results, the study aimed to point out potential prognostic factors of complete or partial response to the initial three months of chemotherapy in palliative colorectal (CRC) cancer.
View Article and Find Full Text PDFApplication of low-coverage whole-genome sequencing technology in risk stratification of colorectal adenomas.
Front Oncol
August 2025
Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing University, Jiaxing, Zhejiang, China.
Objective: The diagnosis of precancerous lesions of colorectal cancer (CRC) presents significant challenges in clinical practice. In this study, we conducted a clinical investigation using the UCAD technique after analyzing chromosomal copy number variations (CNVs) in formalin-fixed, paraffin-embedded (FFPE) samples from various pathological stages, aiming to evaluate the value of detecting chromosomal instability (CIN) in CRC diagnosis.
Methods: Based on colonoscopic pathological findings, we selected 39 FFPE specimens of tubular adenomas, 8 FFPE specimens of villous adenomas, 16 cases diagnosed as tubular-villous adenomas, and 14 cases without defined pathological subtype classification.
A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028.
Front Immunol
September 2025
Department of Clinical Oncology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Background: Neoantigen-based vaccines show promising therapeutic potential in solid tumors such as melanoma, GBM, NSCLC, and CRC. However, clinical responses remain suboptimal in stage IV patients, due to ineffective T-cell function and high tumor burdens. To overcome these limitations, our study investigates a combination strategy using neoantigen peptide vaccines and precision critical lesion radiotherapy (CLERT), which delivers immunomodulatory doses to key tumor regions synergistically enhance immune activation and inhibit progression in multifocal stage IV patients.
View Article and Find Full Text PDFGut microbiota interplay with autophagy-EMT dynamics in colorectal cancer.
Front Cell Dev Biol
August 2025
Department of Epidemiology, Preclinical Research and Advanced Diagnostics, National Institute for Infectious Diseases IRCCS "L. Spallanzani", Rome, Italy.
The human microbiota is composed of a complex community of microorganisms essential for maintaining host homeostasis, especially in the gastrointestinal tract. Emerging evidence suggests that dysbiosis is linked to various cancers, including colorectal cancer (CRC). The microbiota contributes to CRC development and progression by influencing inflammation, genotoxic stress, and key cell growth, proliferation, and differentiation pathways.
View Article and Find Full Text PDF